Arcus Biosciences Inc (NYSE:RCUS) Share Price

Company Profile

Business description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Contact
3928 Point Eden Way
HaywardCA94545
USA
T: +1 510 694-6200
E: [email protected]
https://www.arcusbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
674

Recommended

The stocks of these high-quality companies with large market capitalizations look undervalued today.

Margaret Giles | 02 February 2026

Prices of these shares exceed our Fair Value Estimate by more than double.

Morningstar | 02 February 2026

Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.

Robert M. Almeida | 02 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,068.80	42.20	-0.46%
CAC 40	8,090.98	35.55	-0.44%
DAX 40	24,438.74	100.07	-0.41%
Dow JONES (US)	48,892.47	179.09	-0.36%
FTSE 100	10,174.84	48.70	-0.48%
HKSE	26,775.57	611.54	-2.23%
NASDAQ	23,461.82	223.30	-0.94%
Nikkei 225	52,655.18	667.67	-1.25%
NZX 50 Index	13,412.44	10.74	-0.08%
S&P 500	6,939.03	29.98	-0.43%
S&P/ASX 200	8,778.60	42.50	-0.48%
SSE Composite Index	4,015.75	102.20	-2.48%